A comprehensive listing of bioactivation pathways of organic functional groups.

The occurrence of idiosyncratic adverse drug reactions during late clinical trials or after a drug has been released can lead to a severe restriction in its use and even in its withdrawal. Metabolic activation of relatively inert functional groups to reactive electrophilic intermediates is considered to be an obligatory event in the etiology of many drug-induced adverse reactions. Therefore, a thorough examination of the biochemical reactivity of functional groups/structural motifs in all new drug candidates is essential from a safety standpoint. A major theme attempted in this review is the comprehensive cataloging of all of the known bioactivation pathways of functional groups or structural motifs commonly utilized in drug design efforts. Potential strategies in the detection of reactive intermediates in biochemical systems are also discussed. The intention of this review is not to "black list" functional groups or to immediately discard compounds based on their potential to form reactive metabolites, but rather to serve as a resource describing the structural diversity of these functionalities as well as experimental approaches that could be taken to evaluate whether a "structural alert" in a new drug candidate undergoes bioactivation to reactive metabolites.

[1]  E. Costa,et al.  Transmitter amino acid receptors : structures, transduction, and models for drug development , 1991 .

[2]  A. Kalgutkar,et al.  On the diversity of oxidative bioactivation reactions on nitrogen-containing xenobiotics. , 2002, Current drug metabolism.

[3]  R. Harbison,et al.  Human microsomal N-oxidative metabolism of cocaine. , 1991, Drug metabolism and disposition: the biological fate of chemicals.

[4]  J. Oates,et al.  Covalent binding of procainamide in vitro and in vivo to hepatic protein in mice. , 1981, Drug metabolism and disposition: the biological fate of chemicals.

[5]  R. Haddock,et al.  Metabolic pathway of paroxetine in animals and man and the comparative pharmacological properties of its metabolites , 1989, Acta psychiatrica Scandinavica. Supplementum.

[6]  Curtis D. Klaassen,et al.  Casarett and Doull's Toxicology. The Basic Science of Poisons , 1981 .

[7]  D. Jerina,et al.  Studies on the metabolism of benzo[a]pyrene and dose-dependent differences in the mutagenic profile of its ultimate carcinogenic metabolite. , 1994, Drug metabolism reviews.

[8]  G. Murray,et al.  The role of cytochrome P450 in cytotoxic bioactivation: future therapeutic directions. , 2004, Current cancer drug targets.

[9]  S. Kolis,et al.  The metabolism of 14C-methoxsalen by the dog. , 1979, Drug metabolism and disposition: the biological fate of chemicals.

[10]  R. Obach,et al.  Drug Metabolizing Enzymes : Cytochrome P450 and Other Enzymes in Drug Discovery and Development , 2003 .

[11]  M. Pirmohamed,et al.  Are chemically reactive metabolites responsible for adverse reactions to drugs? , 2002, Current drug metabolism.

[12]  Y. Moriwaki,et al.  Immunohistochemical localization of aldehyde and xanthine oxidase in rat tissues using polyclonal antibodies , 2005, Histochemistry and Cell Biology.

[13]  G. Yost,et al.  Metabolism of 3-methylindole in human tissues. , 1991, Drug metabolism and disposition: the biological fate of chemicals.

[14]  A. Nanji,et al.  Free radical formation during ketamine anesthesia in rats: a cautionary note. , 1998, Free Radical Biology & Medicine.

[15]  B. Ames,et al.  Assays for 8-hydroxy-2'-deoxyguanosine: a biomarker of in vivo oxidative DNA damage. , 1991, Free radical biology & medicine.